Independent Chair Profile Director since 2020 FDA Commissioner (2017 2019) Age: 53 Board Committees Nominating/Corporate Governance Education B.A. in Economics from Wesleyan University M.D. from Mount Sinai School of Medicine of New York University Relevant Expertise Dr. Gottlieb s extensive policy expertise, including his experience as FDA Commissioner from 2017-2019, contributes to the Board s deeper understanding of the risks and opportunities associated with offering FDA-regulated products especially as our growth continues to become more dependent on clinically approved products. Career Highlights Partner, New Enterprise Associates and senior fellow at AEI, a public policy think tank (since 2019) 23rd Commissioner, FDA (2017 2019) Various roles in the public and private sectors including serving as Venture Partner at New Enterprise Associates (2007 2017) FDA Deputy Commissioner for Medical and Scientific Affairs (2005 2007) Senior Advisor for Medical Technology to the FDA Commissioner (2003 2004) Public Board Service Pfizer, Inc. (since 2019) Tempus AI, Inc. (since 2019) UnitedHealth Group (since 2025) Non-Public Board Service Mount Sinai Medical System, Inc. (since 2023) Commanche Biopharma (since 2023) National Resilience, Inc. (since 2020) Xaira Therapeutics (since 2024) Aetion, Inc (2019 2025) Of Note Columnist, Wall Street Journal Contributor to CNBC and CBS Face the Nation Elected Member of the National Academy of Medicine